title: A randomized study comparing IGL-1 to the University of Wisconsin preservation solution in liver transplantation.
abstract: BACKGROUND
  Institut Georges Lopez-1 (IGL-1) is a new preservation solution with lower potassium and lower viscosity than University Wisconsin solution (UW). These characteristics which improve liver preservation lead us to evaluate clinical effects of IGL-1 in a randomized controlled study with UW.
  
  
  METHODS
  From June 2007 to July 2009, after exclusion of partial graft, combined transplantation and fulminant hepatic failure, 140 deceased donor allografts were randomly assigned to IGL-1 (n=48) or UW (n=92) solution. Variables concerning donors and recipients were collected including liver tests (total serum bilirubin, prothrombin time and transaminases) were analyzed until postoperative day 30. Incidences of hepatic artery thrombosis (HAT), primary non function (PNF) and biliary non anastomotic strictures (NAS) were analyzed. The comparative analysis of costs was realized.
  
  
  RESULTS
  Donor and recipients characteristics were similar in both groups. Volume of preservation solution utilized for harvesting was identical. Duration of cold ischemia (472±142 vs. 477±122 min), surgery (427±97 vs. 437±94 min) and proportion of extended criteria donor was similar. Postoperative kinetic and level liver tests were similar. Rate of PNF (2% vs. 4%), early retransplantation (6% vs. 7%), incidence of biliary NAS (2% vs. 3%) and HAT (6% vs. 4%) were similar. Mean intensive care unit (ICU) stay was similar (5.6 vs. 6.1 days). However costs related to preservation solution for one liver procurement were 992.0 for IGL-1 vs. 1609.0 Euros for UW.
  
  
  CONCLUSIONS
  Results of this randomized study shows that the efficacy and safety of IGL-1 are comparable to those of the reference UW with a lower cost.
authors.affiliation: Beaujon Hospital, Assistance Publique Hôpitaux de Paris, Clichy, France.
authors.forename: Fédérica
authors.initials: F
authors.lastname: Dondéro
authors.forename: Catherine
authors.initials: C
authors.lastname: Paugam-Burtz
authors.forename: Fabrice
authors.initials: F
authors.lastname: Danjou
authors.forename: Jeanick
authors.initials: J
authors.lastname: Stocco
authors.forename: Francois
authors.initials: F
authors.lastname: Durand
authors.forename: Jacques
authors.initials: J
authors.lastname: Belghiti
mesh_terms: D000241:Adenosine / Q000737:chemistry / Q000191:economics / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000493:Allopurinol / Q000737:chemistry / Q000191:economics / Q000494:pharmacology; D002648:Child; D005260:Female; D005978:Glutathione / Q000737:chemistry / Q000191:economics / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000737:chemistry / Q000191:economics / Q000494:pharmacology; D008099:Liver / Q000502:physiology*; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions / Q000737:chemistry / Q000191:economics / Q000494:pharmacology*; D011184:Postoperative Period; D011446:Prospective Studies; D011887:Raffinose / Q000737:chemistry / Q000191:economics / Q000494:pharmacology; D014019:Tissue Donors / Q000706:statistics & numerical data; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C504757:IGL-1 solution; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose